Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS ProgramDiabetologia 2021 Nov 01;64(11)2402-2414, TK Young, JW Li, A Kang, HJL Heerspink, C Hockham, C Arnott, BL Neuen, S Zoungas, KW Mahaffey, V Perkovic, D de Zeeuw, G Fulcher, B Neal, M Jardine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.